![]() |
|
|
Vol. 292, Issue 1, 247-253, January 2000
Departments of Renal Pharmacology (P.N., H.-L.W., D.Y.) and Molecular Biology (A.G., N.E.), SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania
| |
Abstract |
|---|
|
|
|---|
Screening of porcine cerebellum cDNA library with porcine endothelinB (ETB) receptor cDNA revealed a novel ETB receptor cDNA that is distinctly different from the wild-type ETB receptor in length and the amino acid sequence at the C-terminal end. This sequence appears to represent alternate splicing of the carboxy terminal end of ETB receptor, resulting in a polypeptide of 429 amino acids in length, which is 14 amino acids shorter than the wild-type porcine ETB receptor. Characterization of the wild-type and alternately spliced ETB receptors expressed in COS cells revealed that both receptors displayed very similar binding [apparent dissociation constant (Kd) and maximum binding (Bmax) for 125I-ET-1 were 71 pM and 1.6 pmol/mg protein for wild-type and 81 pM and 1.2 pmol/mg protein for splice variant ETB receptors] as well as functional properties. These data suggest that the differences in the amino acids at the C-terminal end had no effect on binding or functional coupling of these alternately spliced ETB receptors.
| |
Introduction |
|---|
|
|
|---|
Endothelins
(ET), a family of peptide hormones, originally identified by Yanagisawa
et al. (1988)
, exert a number of physiological effects, including
potent vasoconstriction, transient vasodilation, proliferation, and
neuroregulatory functions (Simonson and Dunn, 1990
; Rubanyi and Parker
Bothels, 1991
). This family consists of three members, ET-1, ET-2, and
ET-3, that are encoded by three separate genes (Inoue et al., 1989
).
Soon after the discovery of ET peptides, a family of 21 amino acid
peptide toxins (sarafotoxins) that shared a high degree of homology to
ET was identified (Kloog and Sokolovsky, 1989
). The biological effects
of these peptides are mediated by specific cell surface G
protein-coupled receptor superfamily. Based on the binding profiles of
ETs and sarafotoxins, three ET receptors (ETA,
ETB, and ETC) have been
cloned and characterized (Arai et al., 1990
; Sakurai et al., 1990
;
Karne et al., 1993
). Although ETA and
ETB receptors have been cloned from a number of
species, including human (Adachi et al., 1991
; Lin et al., 1991
; Saito
et al., 1991
; Elshourbagy et al., 1992
, 1993
),
ETC receptors have been identified only in
Xenopus (Karne et al., 1993
). ETB
receptors display similar affinities for ET-1, ET-2, ET-3, and
sarafotoxin 6c (S6c), whereas ETA receptors
display similar affinity for ET-1 and ET-2, 100-fold lower affinity for ET-3, and >1000-fold lower affinity for S6c. ETC
receptors have been shown to bind ET-3 with much higher affinity than
ET-1 (Karne et al., 1993
). In addition to ETC,
another subtype of ET receptors (ETAX) has been
cloned and characterized from Xenopus heart (Kumar et al.,
1994
). These receptors, although maintaining the pharmacological characteristics of ETA receptors for ET-3 and
S6c, display extremely low affinity to BQ123, originally identified as
an ETA-selective antagonist (Ihara et al., 1992
).
Also, a number of alternately spliced forms of ET receptors have been
identified and characterized. Cheng et al. (1993)
reported an
alternately spliced form of ETB receptors from
rat brain. Compared with the wild-type receptor, this receptor had four
amino acid substitutions in the amino terminal end, and the 5'- and
3'-noncoding regions were different. The binding profiles for various
agonists were the same for these two receptors, although no functional
data were reported (Cheng et al., 1993
). An alternately spliced form of
human ETB receptors was reported by Elshourbagy
et al. (1996)
and Shyamala et al. (1994)
. Although the splice variant
reported by Shyamala et al. (1994)
had 10 additional amino acids in the
second cytoplasmic domain, there were no differences in binding as well
as functional parameters between the splice variant and wild-type
receptors (Shyamala et al., 1994
). However, the splice variant of human ETB receptors reported by Elshourbagy et al.
(1996)
showed significant differences in the last 52 amino acids at the
carboxy terminal. Although the binding parameters between this
alternately spliced form and wild-type ETB
receptors were the same, the splice variant of
ETB receptors was functionally uncoupled
(Elshourbagy et al., 1996
). The data presented herein demonstrates the
presence of an additional splice variant of porcine
ETB receptor. This receptor shows significant
differences in the last 32 amino acids at the carboxy terminal compared
with wild-type porcine ETB receptors. Furthermore, the binding and functional characteristics of this receptor are identical with the wild-type ETB receptor.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials. 125I-ET-1 and 125I-IRL-1620 (specific activities, 2200 Ci/mmol) were obtained from New England Nuclear (Boston, MA). Unlabeled ET-1, ET-3, and S6c were from American Peptides (Santa Clara, CA). All other reagents were of the highest grade available.
Construction and Screening of cDNA Libraries.
The porcine
cerebellum cDNA library (Elshourbagy et al., 1992
) in pcDNA vector was
screened by hybridization to nitrocellulose replicates with
32P-labeled porcine ETB-R
cDNA coding sequence as a probe in 20% formamide, 5× SSC (SSC is 150 mM NaCl, 15 mM sodium citrate), 5× Denhardt's, 0.1% SDS, and 0.2 mg/ml Escherichia coli tRNA at 42°C (Elshourbagy et al.,
1990
). Filters were washed with 2× standard saline citrate,
0.1% SDS at 42°C. Several positive recombinant clones were isolated
from the porcine cerebellum library and characterized. Preliminary
sequence analysis showed that six of these clones encode the
ETB-R clones, except for two clones that contain
the same 5'-coding region of ETB-R and a
divergent 3'-coding sequence.
Nucleotide Sequence Analysis.
The inserts of the porcine
ETB splice variant receptor (SVR)560 were
sequenced on both strands with a modification of the dideoxy chain
termination method (Sanger et al., 1977
) with the Sequenase II kit (US
Biochemical Corp., Cleveland, OH). The Wisconsin Genetics Computer
Group Software package (Devereux et al., 1984
) was used to assemble
composite sequences from the various fragments and for future sequence analysis.
RNA Blot Analysis.
For Northern analysis,
poly(A)+ RNA was isolated from various porcine
tissues with the guanidinum thiocyanate acid-phenol method (Chomczynski
and Sacchi, 1987
). One microgram of each RNA was fractionated on 1%
agarose formaldehyde gels (Lehrach et al., 1977
) and transferred to
nitrocellulose membranes. Northern hybridizations were performed at
42°C in 50% formamide, 5% subacute sclerosing panencephalitis, 5×
Denhardt's reagent, 0.1% SDS, and 100 µg/ml yeast tRNA (Elshourbagy
et al., 1985
). The blots were washed with 0.1× standard saline
citrate, 0.1% SDS at 50°C and exposed to X-ray film for 4 days at
70°C. Autoradiograms were analyzed by quantitative scanning densitometry.
Expression of Porcine ETB Receptors in COS
Cells.
Fragments containing the entire porcine
ETB-SVR cDNA and ETB-R cDNA
coding sequence was subcloned into the mammalian expression vector
pRLDN (Elshourbagy et al., 1993
). COS cells grown in 245 × 245-mm
tissue culture plates were transfected with 75 µg of porcine
ETB-SVR or porcine ETB-R
cDNA and grown in Dulbecco's modified Eagle's medium supplemented
with 10% fetal bovine serum for 2 days as previously described
(Elshourbagy et al., 1992
).
Membrane Preparation.
COS cells transfected with wild type
as well as splice variant of porcine ETB
receptors were washed with Dulbecco's phosphate-buffered saline
containing a protease inhibitor cocktail (5 mM EDTA, 0.5 mM
phenylmethylsulfonyl fluoride, 5 µg/ml leupeptin, and 0.1 µg/ml aprotinin) and scraped in the same buffer. The membranes were prepared
following the procedure of Elshourbagy et al. (1993)
. Protein was
estimated by bicinchoninic acid method.
Radioligand-Binding Studies.
125I-ET-1
and 125I-IRL-1620 binding to COS cell membranes
were performed following the procedure of Elshourbagy et al. (1993)
with the following modifications. The assay volume was 50 µl and the protein used was 50 to 100 ng/tube. Each experiment was done three times with membranes prepared from different transfections. The data
presented are from one representative experiment.
Phosphoinositide Turnover.
COS cells transfected with
wild-type and splice variant porcine ETB receptor
clones were treated with 1 µCi/ml myo
[3H]inositol for 24 h in serum-free
medium. At the end of the treatment, the medium was removed, cells were
washed with Dulbecco's phosphate-buffered saline, and then exposed to
indicated concentrations of agonist for 10 min at 37°C. The reactions
were stopped with 10% trichloroacetic acid, and the inositol
phosphates were separated with ion exchange chromatography following
the procedure of Aiyar et al. (1986)
.
Desensitization with ET-1 or Pretreatment with Phorbol-12,13-Dibutyrate (PDBu). COS cells transfected with wild-type and splice variant procine ETB receptor clones were treated with 100 nM PDBu or 0.3 nM ET-1 for 30 min at 37°C. At the end of treatment, the medium was removed, cells were washed with Dulbecco's phosphate-buffered saline, and processed for binding assays (membranes) or functinal assays (inositol phosphate measurements).
| |
Results |
|---|
|
|
|---|
The deduced polypeptide of the alternately spliced form of porcine
ETB (ETB-SVR) receptor
consisted of 429 amino acid residues with a calculated molecular mass
of ~47.2 kDa (Fig. 1). This is different from the size of the wild-type porcine
ETB receptor, which is 443 amino acids with a
calculated molecular mass of 49 kDa (Fig. 1). Northern blot analysis
and tissue distribution studies indicated the presence of two major
bands (4.4 and 1.7 kilobases) corresponding to the full-length
ETB receptor clones. These could have resulted
from two polyadenylation signals that are 32 and 29 base pairs upstream
of the polyadenylation sites of the two mRNA species. The additional
band at 2.35 kilobases corresponds to the size of the splice variant
ETB receptor. The three mRNA species appeared to
be higher in the lung, kidney, cerebellum, and to a lesser extent in
the cerebral cortex, pituitary, liver, uterine body, right atria, right
ventricle, and the whole heart (Fig. 2).
|
|
Addition of increasing concentrations of
125I-ET-1 or 125I-IRL-1620
(ETB-selective agonist) to membranes prepared
from COS cells transfected with wild-type or splice variant porcine
receptor clones resulted in specific, saturable, and high affinity
binding as shown in Figs. 3 and
4 (top and middle) for
125I-ET-1 and
125I-IRL-1620, respectively. The Scatchard
transformation of the specific-binding data from saturation-binding
experiments is presented in Figs. 3 and 4 (bottom). The apparent
dissociation constant (Kd) and maximum
binding (Bmax) for
125I-ET-1 were 71 pM and 1.6 pmol/mg protein for
wild-type and 81 pM and 1.2 pmol/mg protein for splice variant
ETB receptors (Fig. 3; bottom). Under the
same conditions, 125I-IRL-1620 gave
Kd and
Bmax values of 124 pM and 1.2 pmol/mg
protein, respectively, for wild-type and 158 pM and 1.1 pmol/mg
protein, respectively, for splice variant ETB
receptors (Fig. 4; bottom). Competition-binding experiments with
unlabeled ET-1, IRL-1620 [ETB-selective agonist
(Takai et al., 1992
; Nambi et al., 1994
)], and RES701
[ETB-selective antagonist (Tanaka et al.,
1994
)] displayed identical binding profiles when tested against both
receptors (Fig. 5). Untransfected
or vector-transfected COS cells did not display any
125I-ET-1 binding. No dissociation of bound
125I-ET-1 was observed for wild-type and splice
variant receptor (data not shown).
|
|
|
Exposure of [3H]myoinositol-labeled COS cells
expressing wild-type as well as splice variant porcine
ETB receptors to increasing concentrations of
ET-1 resulted in a concentration-dependent increase in the accumulation
of inositol phosphates as shown in Fig.
6. The concentration-response curves for
ET-1 were identical for the two ETB receptors,
indicating that the differences in the amino acids at the C-terminal
end had no effect on the functional coupling of these receptors. ET-1
did not stimulate or inhibit inositol phosphates accumulation in
untransfected or vector-transfected COS cells.
|
Experiments also were performed to test whether there were any differences in the regulation of these two receptors. Desensitization of these receptors by pretreating with ET-1 followed by rechallenge with ET-1 resulted in a 34.7% decrease in binding and a 35.3% decrease in inositol phosphates accumulation for wild-type and a 38% decrease in binding and a 41.6% decrease in inositol phosphates accumulation for splice variant receptor. There were no significant changes in Kd values for binding or EC50 values for function between control and desensitized receptors.
Similarly, pretreatment of these receptors with PDBu (an activator of protein kinase C) resulted in a 41.5 and 66.8% decrease in binding and inositol phosphates accumulation, respectively, for wild-type and a 28.4 and 36% decrease in binding and inositol phosphates accumulation, respectively, for splice variant receptors. Exposure of wild-type or splice variant ETB receptors to ET-1 had no effect on intracellular accumulation of cAMP (data not shown).
| |
Discussion |
|---|
|
|
|---|
The porcine ETB receptor cDNA, previously
cloned in our laboratory (Elshourbagy et al., 1992
) was used to probe
porcine cerebellum cDNA library. Many positive clones were identified
and nucleotide sequence analysis revealed that several of these
positive clones encoded for ETB-R, except for two
novel ETB-R clones that differed in the length
and the amino acid sequence at the 3'-coding region. Sequence analysis
of these clones revealed an identical sequence to the
ETB receptor from the 5'-untranslated region
through the putative seventh transmembrane domain (7TM). The sequence
then diverged completely in the cytoplasmic domain and 3'-untranslated region. Several independent clones in our library were found to contain
this sequence, which appears to represent an alternate splicing of the
carboxy-terminal tail of the ETB receptor.
Similar to the human ETB-SVR (Elshourbagy et al.
1996
), the 3'-terminal tail of the porcine
ETB-SVR clone was found to correspond to the extreme 3'-untranslated region of wild-type
ETB-R. Analysis of the
ETB-R genomic structure (Arai et al., 1993
)
revealed a similar splicing mechanism to that observed in the human
ETB-R splice variant reported by Elshourbagy et
al. (1996)
, namely, exons 1 through 6 are identical in
ETB-SVR and the ETB-R in
terms of their nucleotide sequence composition and their splice site.
The carboxy-terminal tail of the procine and human
ETB-SVR correspond to the extreme 3'-untranslated
region of the ETB-R. However, the location of the
splicing site of the porcine and the human are different; namely the
putative splice site in the human and the porcine use an A(G/G)C and
A(G/G)G only four nucleotides away from each other at the 3'-acceptor
site. As a result, the 3'-coding region of the porcine
ETB-SVR and the human
ETB-SVR are different. Thus, two putative splice
sites were identified at exon 7 in the porcine ETB receptor gene; the first splice site produced
a 2925-bp exon that encodes the normal ETB-R, and
the second splice site produced a 1151-bp exon that encodes the
ETB-SVR.
Receptor subtypes can arise through divergent genes, e.g.,
ETA and ETB and in the case
of intron-containing genes, additional variants within a subtype can
arise by alternative RNA splicing. Recent studies have identified an
ETB receptor variant that contains an additional
10 amino acids in the second cytoplasmic domain of the
ETB receptor (Shyamala et al., 1994
). This
sequence was part of the ETB receptor intron that
separates the second and third exons and therefore arises by
alternative RNA splicing of a single gene. The identification of splice
variants among the seven TM receptors has been increasing at a
phenomenal rate following the initial observation of two variant forms
for dopamine D2 receptor (Sibley and Monsma, 1992
). Recent splice
variants have been identified for thyrotropin-stimulating hormone (THR)
(de la Pena et al., 1992
), neurokinin receptors (Fong et al., 1992
),
prostaglandin EP3 receptor (Sugimoto el al., 1993
; Namba et al., 1993
),
pituitary adenylyl cyclase-activating polypeptide (PACAP receptor)
(Spengler et al., 1993
), and monocyte chemoattractant protein (MCP-1)
receptor (Charo et al., 1994
). It is interesting to note that in all
these examples, the cytoplasmic domain of the receptor is altered,
suggesting that alternative RNA splicing may play a role in the
generation of physiologically divergent receptor activity for the same
ligand. However, there is no experimental data to support this.
Radioligand binding data indicated that these two receptors are expressed at the same level with similar affinities, suggesting that the modifications present at the carboxyl terminal of the receptor did not influence the binding of agonists or antagonists. This is not surprising because the binding of agonists and/or antagonists to 7TM G protein-coupled receptors is predicted to be at the extracellular and, in some cases, TM regions, whereas the functional coupling to the second messenger systems is predicted to be at the intracellular domain.
Contrary to what we have reported for human ETB
receptor splice variant (Elshourbagy et al., 1996
), porcine
ETBR and ETBSVR behaved
very similarly in their functional response (stimulation of inositol
phosphates accumulation). The critical requirements of palmitoylation
and phosphorylation for signal transduction pathways are not clear. A
careful comparison of the C-terminal region of wild-type and splice
variant porcine ETB receptors reveals that the
wild-type receptor contains 9 Ser, 5 Cys, 2 Tyr, and 0 Thr, whereas
splice variant receptor contains 2 Ser, 2 Cys, and 2 Thr. In addition,
the splice variant receptor is 14 amino acids shorter than the
wild-type ETB receptor. The observation that
wild-type as well as splice variant ETB receptors
display very similar binding and functional properties suggests that
neither the truncated C-terminal tail nor the changes in amino acids
contribute to the binding or function of these receptors. Mutation of
the Cys residues at the C-terminal end of a number of 7TM G
protein-coupled receptors have resulted in different functional
responses. Although mutation of the Cys residue at the C-terminal end
of
-adrenergic (O'Dowd et al., 1989
) and ETB
(Koshimizu et al., 1995
) receptors resulted in the loss of function of
these mutated receptors, mutations of Cys residues of vasopressin
V2 receptors (Sadeghi et al., 1997
),
-2
adrenergic receptors (Kennedy and Limbird, 1993
), dopamine D1 receptors
(Jin et al., 1997
), lutenizing hormone/human choriogonadotropin receptors (Kawate et al., 1997
), and thyrotropin receptors (Kosugi and
Mori, 1996
) had no significant effect on the functional coupling of
these receptors. These data clearly suggest that although
palmitoylation of Cys residues is critical for certain receptors, it is
not required for many other receptors for successful functional
coupling. Koshimizu et al. (1995)
reported the critical requirement of
one Cys (amino acid 402) for functional coupling of human
ETB receptors. This conclusion was based on the
generation of a number of C-terminal mutants. It is possible that in
the alternatively spliced porcine ETB receptors,
this critical requirements of the Cys residue could have been satisfied
by the Cys present in positions 409 or 410.
For a number of G protein-coupled receptors, the mechanism of
desensitization appears to be phosphorylation of the receptors on
serine and threonine residues by at least two classes of protein kinases. These are second messenger-activated kinases such as cAMP-dependent protein kinase or protein kinase C and a family of G
protein-coupled receptor kinases (GRK). These kinases have been shown
to preferentially phosphorylate residues in certain sequences. For
example, cAMP-dependent protein kinase prefers RXS, RRXS, RXXS, or
KRXXS, whereas protein kinase C prefers K/RXXS/T, S/TXK/R, K/RXS/T, or
K/RXS/TXK/R. However, GRKs are classified as acidotropic kinases
because of their preference for acidic amino acids proximal to
phosphorylatable residues (EDST, EESSSS, EESV). Similar to several G
protein-coupled receptors, ETA and ETB receptors each have cytoplasmic
carboxy-terminal domains rich in serines and threonines. Because the
homology between ETA and ETB receptors at the cytoplasmic tail is
relatively low, it is possible that these receptors might be regulated
differentially by GRKs. However, studies performed with cytoplasmic
tail truncation mutants of ETA (Cyr et al., 1993
)
and ETB receptors (Koshimizu et al., 1995
)
suggest that agonist-mediated desensitization was unaffected by the
removal of large portion of cytoplasmic tail of each receptor. The data
presented in this report also suggest that there was no difference
between wild-type and splice variant ETB receptor
in ET-mediated desensitization or phorbol ester-mediated regulation,
suggesting that the amino acid changes or C-terminal truncation of 14 amino acids did not have any effect on ET binding, function, or regulation.
| |
Acknowledgments |
|---|
We would like to thank Ganesh Sathe, Joyce Mao, and Stephanie Vanhorn for oligonucleotide synthesis and sequencing, and Sue Tirri and Maria McDevitt for excellent secretarial assistance.
| |
Footnotes |
|---|
Accepted for publication August 11, 1999.
Received for publication December 22, 1998.
1 Present address: Cardiovascular Sciences, DuPont Pharmaceuticals Company, Experimental Station, E 400/3237, Wilmington, DE 19880-0400.
Send reprint requests to: Ponnal Nambi, Ph.D., Cardiovascular Sciences, DuPont Pharmaceuticals Company, Experimental Station, E 400/3237, Wilmington, DE 19880-0400.
| |
Abbreviations |
|---|
ET, endothelin; S6c, sarafotoxin 6c; ETB-SVR, ETB splice variant receptor; bp, base pair; PDBu, phorbol-12,13-dibutyrate; TM, transmembrane; GRK, G protein-coupled receptor kinases.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
N. Hatae, N. Aksentijevich, H. W. Zemkova, K. Kretschmannova, M. Tomic, and S. S. Stojilkovic Cloning and Functional Identification of Novel Endothelin Receptor Type A Isoforms in Pituitary Mol. Endocrinol., May 1, 2007; 21(5): 1192 - 1204. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Perron, P. Sarret, L. Gendron, T. Stroh, and A. Beaudet Identification and Functional Characterization of a 5-Transmembrane Domain Variant Isoform of the NTS2 Neurotensin Receptor in Rat Central Nervous System J. Biol. Chem., March 18, 2005; 280(11): 10219 - 10227. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Taylor, C. E. Gariepy, D. M. Pollock, and J. S. Pollock Unique endothelin receptor binding in kidneys of ETB receptor deficient rats Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2003; 284(3): R674 - R681. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Tanoue, T.-a. Koshimizu, M. Tsuchiya, K. Ishii, M. Osawa, M. Saeki, and G. Tsujimoto Two Novel Transcripts for Human Endothelin B Receptor Produced by RNA Editing/Alternative Splicing from a Single Gene J. Biol. Chem., August 30, 2002; 277(36): 33205 - 33212. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Davenport International Union of Pharmacology. XXIX. Update on Endothelin Receptor Nomenclature Pharmacol. Rev., June 1, 2002; 54(2): 219 - 226. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||